 Home > Medical News > Medical World News > Nuocheng Jianhua Obutinib Obtained NMPA Approval to Start Phase II Clinical Study for Treatment of Multiple Sclerosis

Nuocheng Jianhua Obutinib Obtained NMPA Approval to Start Phase II Clinical Study for Treatment of Multiple Sclerosis

 Last Update: 2021-05-02
 Source: Internet
 Author: User

Tags

international patent

1 octen 3

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Nuocheng Jianhua announced today that the company's Bruton's tyrosine kinase (BTK) inhibitor abutinib for the treatment of multiple sclerosis (MS) has passed the China National Medical Products Administration (NMPA) clinical research new drug (IND) review and approved to conduct Phase II clinical studies in China.

This is an international multi-center clinical phase II study evaluating the use of abutinib in patients with multiple sclerosis.

MS is an autoimmune central nervous system disease.

According to data released by the Multiple Sclerosis International Federation (MSIF), more than 2.

^[1]^[2]

According to the Comprehensive Social Survey Report on Patients with Multiple Sclerosis in China in 2020, more than 43% of patients are unable to take care of themselves and need care by others.

^[3]

[1] Data source: Multiple Sclerosis International Federation (MSIF) official website

[1] Data source: Multiple Sclerosis International Federation (MSIF) official websitestyle="text-indent:2em;margin-top:20px;"> [2] Data source: Frost & Sullivan analysis

[2] Data source: Frost & Sullivan analysis

[3] Data source: China Rare Disease Alliance: "2020 Comprehensive Social Survey Report on Patients with Multiple Sclerosis in China"

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.